A Phase 1, Multicenter, Open-Label, Dose Escalation Study Evaluationg the Safety and Tolerability of EZN-2968, a Locked Nucleic Acid Antisense Oligonucleotide Against Hypoxia Inducible Factor-1 alpha (anti-HIF-1 alpha LNA AS-ODN), Administered as a Daily 2-Hour Intravenous Infusion x 5 Days Every 4 Weeks in Adult Patients with Advanced Solid Tumors or Lymphoma
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2008
At a glance
- Drugs RG 6061 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 11 Nov 2008 New trial record.